OREANDA-NEWS  Specialists of Sirius University have confirmed the effectiveness of the vaccine in the fight against tuberculosis, now scientists are testing the drug on rodents, the press service of the university told reporters.

The creation of a new vaccine was reported by the university in the spring of 2023. Then scientists began to study the drug. Today, according to the university, the vaccine has almost been studied, it remains to conduct only preclinical and clinical trials.

"Specialists of the Scientific Center for Translational Medicine of Sirius University have developed a multi-epitope mRNA vaccine this spring, which can become a new approach to the prevention and treatment of tuberculosis. Now scientists are conducting a number of additional studies on rodents, whose task is to confirm the effectiveness of the developed drug," the report says.
As explained in the press service of the university, the usual vaccine against tuberculosis involves the introduction of a pathogen protein into the body, which is obtained by various biotechnological methods. In the case of a new vaccine, the synthesis of pathogen antigens is carried out naturally in the human body, so it has a high immunogenicity.

"At the moment, the only approved vaccine for the prevention of tuberculosis is BCG (tuberculosis vaccine - ed.). Its main drawback is that it does not provide full protection against pulmonary tuberculosis in adults. The use of BCG for adult revaccination is not recommended by the World Health Organization, since the risk of side effects outweighs the possible benefits ... Our research group, within the grant, has set itself the task of developing an effective alternative to the BCG vaccine," Roman Ivanov, director of the Scientific Center for Translational Medicine at Sirius University, is quoted in the message.